Health & Life Co., Ltd. (1781) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Health & Life Co., Ltd. TWD 1.93, price TWD 10.05, upside -80.8%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Health & Life Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 9.99 TWD – 28.20 TWD · fair‑value band 1.27 TWD – 2.41 TWD · the 10.05 TWD price screens above the 1.93 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Health & Life Co. in your weekly email
Every Wednesday you see whether Health & Life Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Health & Life Co., Ltd. manufactures and sells products for cardiovascular disease, in-vitro diagnostics, and respiratory care worldwide. It offers vibrating mesh nebulizers, blood pressure monitor products, IR thermometers, and hearing aid devices. The company was founded in 1996 and is based in New Taipei City, Taiwan.
Stock analysis
Health & Life Co., Ltd. (1781) currently trades at 10.05 TWD, while our model-based Fair Value estimate is 1.93 TWD, implying the stock looks roughly 420.8% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 1.27 TWD (bear) to 2.41 TWD (bull), the price of 10.05 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Health & Life Co., Ltd. reported revenue of 398M TWD in FY2025 versus 812M TWD in FY2021, a compound −16.3%/yr. Reported net income was −61.7M TWD in FY2025.
Key figures
Market cap 476M TWD (≈ $15.0M) · P/S ratio 1.27 · EPS (TTM) −1.07 TWD · Net margin −15.5% · Return on equity −15.6% · Return on assets (EBIT) −6.4% · Operating margin −16.4% · Revenue (TTM) 400M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −81%, 1781 screens richer than that median.
Fair Value models
Bear 1.27 TWDFair Value 1.93 TWDBull 2.41 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−43.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.7%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11.9% (2021) → −15.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Health & Life Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−81% · Bottom 25%
Profitability
Return on assets−7% · Below median
Net margin (TTM)−13% · Below median
Operating margin (TTM)−16% · Bottom 25%
Growth and dividend
Revenue growth39% · Top 25%
Balance sheet
Debt / equity0.59× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.05× · Cheapest 25%
P/S (TTM)0.04× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)100· sector 31
PAST (return on equity)0· sector 7
HEALTH (low debt)70· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Health & Life Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/1781
Frequently asked questions
Is Health & Life Co., Ltd. (1781) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1.93 TWD versus a price of 10.05 TWD, about −81% upside (overvalued).
What is the fair value of 1781?
Our model-based fair value for Health & Life Co., Ltd. is 1.93 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 10.05 TWD.
What is the quality score of 1781?
Health & Life Co., Ltd. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Health & Life Co., Ltd. (1781)?
Our model-based price target is the fair value of 1.93 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 1.27 TWD, optimistic scenario 2.41 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Health & Life Co., Ltd. stock forecast for 2026?
Our models put fair value at 1.93 TWD, about −81% upside versus a price of 10.05 TWD (overvalued). Cautious scenario 1.27 TWD, optimistic scenario 2.41 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Health & Life Co., Ltd. (1781)?
Health & Life Co., Ltd. reported trailing-twelve-month revenue of about 400M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Health & Life Co., Ltd. (1781)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Health & Life Co., Ltd. it is 1.93 TWD per share (as of Sep 24, 2026), against a price of 10.05 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Health & Life Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1781 trades above its calculated fair value: price 10.05 TWD, fair value 1.93 TWD, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1781?
No. The price is what the market pays today (10.05 TWD); the fair value is what the company's own numbers justify (1.93 TWD). For Health & Life Co., Ltd. the two are 8.12 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Health & Life Co., Ltd. worth?
The market values Health & Life Co., Ltd. at about 476M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 10.05 TWD; our models calculate a fair value of 1.93 TWD per share.
What do the bullish and bearish scenarios say about 1781?
Our models span a range for Health & Life Co., Ltd.: cautious scenario 1.27 TWD, base 1.93 TWD, optimistic 2.41 TWD per share (as of Sep 24, 2026, price 10.05 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Health & Life Co., Ltd. (1781)?
Balance-sheet figures for Health & Life Co., Ltd. (as of Sep 24, 2026): return on equity −15.6%, debt of 0.59 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 1781 from its 52-week high?
Health & Life Co., Ltd. trades at 10.05 TWD, about 26% below its 52-week high of 13.65 TWD and 1% above the low of 9.99 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 1.93 TWD is for.
Which stocks are comparable to Health & Life Co., Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Health & Life Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 10.05 TWD, calculated fair value 1.93 TWD (−81%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1781 calculated?
We run Health & Life Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.93 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Health & Life Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Health & Life Co., Ltd. (1781)?
The closing price on Sep 24, 2026 was 10.05 TWD. Our model-based fair value is 1.93 TWD, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Health & Life Co., Ltd. right now?
The price sits above even our optimistic bull case (2.41 TWD). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1.27 TWD to 2.41 TWD) leaves room in how you read the outcome.
Key figures of Health & Life Co., Ltd.
How large is the market capitalisation of Health & Life Co., Ltd. (1781)?
The market capitalisation of Health & Life Co., Ltd. is 476M TWD (≈ $15.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Health & Life Co., Ltd. (1781)?
The price-to-sales ratio of Health & Life Co., Ltd. is 1.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Health & Life Co., Ltd. (1781)?
Earnings per share at Health & Life Co., Ltd. are −1.07 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Health & Life Co., Ltd. (1781)?
The net margin of Health & Life Co., Ltd. is −15.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Health & Life Co., Ltd. (1781)?
The return on equity (ROE) of Health & Life Co., Ltd. is −15.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Health & Life Co., Ltd. (1781)?
On an EBIT basis the return on assets of Health & Life Co., Ltd. is −6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Health & Life Co., Ltd. (1781)?
The operating margin of Health & Life Co., Ltd. is −16.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Health & Life Co., Ltd. (1781)?
Revenue at Health & Life Co., Ltd. is growing +39.3% versus a year earlier (3y avg −20.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Health & Life Co., Ltd. (1781) generate?
The free cash flow of Health & Life Co., Ltd. is −5.0M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Health & Life Co., Ltd. (1781) carry?
The net debt of Health & Life Co., Ltd. is 4.2M TWD (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Health & Life Co., Ltd. in the live analysis
One click puts Health & Life Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
